Due to health issues, this site is no longer maintained and will be shut down shortly.

REPCF RepliCel Life Sciences Inc.

RepliCel Life Sciences, Inc. operates as a regenerative medicine company. The company focuses on developing autologous cell therapies that address conditions linked to a deficit of healthy cells required for normal healing and function. Its products includes RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aged skin, and pattern baldness. The company was founded on April 24, 1967 and is headquartered in Vancouver, Canada.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.10    Pink
As of 03/23/2023     OTCMarkets

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  
IPO date:  06/03/2004
Outstanding shares:  54,870,560
Average volume:  4,351
Market cap:   $5,717,512
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy